Which factors are associated with falls in people with dementia? Researchers from China investigated this. Their findings provide clear indications of which characteristics to focus on in fall prevention for people with cognitive impairments. While there are numerous studies that examine the risk factors for falls in older individuals...
People with Alzheimer's dementia fall more often than their cognitively healthy peers. Researchers from the USA have now substantiated this finding with a large review. In it, they summarized data on the frequency and number of falls, the reoccurrence rate of falls, and the number of falls that caused injuries. Older people who injured themselves...
Over the years, seniors often experience limitations in their walking ability. These limitations can indicate diseases that are not initially associated with gait disorders. Scientists from France and Canada have now confirmed that gait performance provides „valuable insights“ into the cognitive functions of older people...
What is the risk of an older person developing dementia after a fall? Researchers from the USA found: In 10.6 percent of patients treated for a fall, dementia was diagnosed within one year. Previous studies have already shown a connection between mild cognitive...
In the sixth edition of our special newsletter SCHLAGLICHT – New Medications Against Dementia, Lisa Laininger, research associate at digiDEM Bayern, discusses the publication by Dr. Jeffrey L. Cummings of the University of Nevada Las Vegas and his colleagues, titled Lecanemab: Appropriate Use Recommendations, in the professional journal The Journal of Prevention of Alzheimer’s…
In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
Echte Hilfe für Betroffene oder medialer Hype – was können wir von den neuen Medikamenten zur Behandlung der Alzheimer-Erkrankung wirklich erwarten? Weltweit führen Fachexperten kontroverse Diskussionen über die sogenannten monoklonalen Antikörper, die für die Behandlung von leichten kognitiven Beeinträchtigungen und Alzheimer-Demenz vorgesehen sind. Mit den Fakten aus der Forschung werden …
Gender Studies in medicine is a highly relevant societal topic. This is because gender plays an important role in both the development and treatment of diseases. Gender-specific differences are also evident in dementia patients. For example, women develop dementia more often than men and show a different...
The MAKS® therapy was honored with an MSD Health Award 2024. The MAKS® program, consisting of several components, has been proven to help people with mild to moderate dementia maintain their cognitive abilities for as long as possible. The non-pharmacological activation therapy helps to slow the progression of dementia and alleviate its symptoms. For the award...
Die sogenannte Amyloid-Hypothese hat die Alzheimerforschung über Jahrzehnte hinweg maßgeblich geprägt und zur Entwicklung der ersten Antikörpertherapien geführt. Trotz dieser Fortschritte bleiben die klinischen Erfolge begrenzt, was zunehmend Fragen zur Wirksamkeit und zum tatsächlichen Nutzen dieser Therapien aufwirft. In unserem Webinar hat Prof. Dr. Christian Behl, einer der international renommiertesten …
